Last Updated : October 19, 2023
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1507-000
Question
- What is the clinical effectiveness of semaglutide subcutaneous injection 2 mg once weekly for the management of type 2 diabetes in adults?
- What is the cost-effectiveness of semaglutide subcutaneous injection 2 mg once weekly for the management of type 2 diabetes in adults?
Key Message
For patients with type 2 diabetes mellitus, a single randomized controlled trial (SUSTAIN FORTE) suggested that once-weekly subcutaneous semaglutide 2.0 mg may achieve better glycemic control than once-weekly subcutaneous semaglutide 1.0 mg. However, it is unclear whether between-group differences are clinically meaningful. Gastrointestinal disorders were the most common adverse event resulting in premature discontinuation in both groups. One participant in each study arm experienced a cardiovascular disorder serious enough for premature discontinuation. As most trial patients were white, it is unclear if the results are generalizable to groups with higher prevalence of T2DM in Canada, such as Indigenous peoples or those of South Asian descent. We did not find any studies on the cost-effectiveness of subcutaneous semaglutide 2.0 mg, compared to placebo or other doses of semaglutide.
Files
Last Updated : October 19, 2023